BioSpace - News

NEWSLETTERS
FREE Newsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News

CAREER NETWORK
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
askHR
For Employers

DIVERSITY

HOTBEDS
Regional News
Biotech Bay™
Biotech Beach™
Genetown™
Pharm Country™
BioCapital™
BioMidwest™
Bio NC™
BioForest™
Southern Pharm™
BioCanada East™

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
BioPharm Insight

INDUSTRY EVENTS
Biotech Events

RESOURCES
Real Estate
New Business Opportunities

<< Back |

Eisai's Canadian Sales Subsidiary Celebrates Official Introduction to Canada

Tokyo, Dec 1, 2011 (JCN Newswire) - Eisai Co. Ltd announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited held a ceremony on November 30 (local time in Toronto) to celebrate its official opening and entry into the Canadian healthcare marketplace.

Eisai Canada was established in Mississauga, Ontario, one of largest biopharmaceutical clusters and medical communities in North America, in April 2010 as Eisai's first pharmaceutical sales base for the Canadian market.

Having commenced fully-fledged operations earlier this year, Eisai Canada has already launched the antiepileptic agent Banzel as well as the chemotherapeutic implant Gliadel Wafer for the treatment of certain malignant brain tumors, and has filed a New Drug Submission (NDS) with the Canadian regulatory authorities for the anticancer agent Halaven, one of Eisai's major global products. From next year onwards, Eisai Canada also plans to submit NDSs for the AMPA receptor antagonist perampanel (generic name) and a range of other additional new products in the fields of oncology and neurology, Eisai's defined areas of global therapeutic focus, thereby expanding its Canadian product portfolio.

As part of the company's great globalization strategy set out in its mid-term strategic plan "HAYABUSA", Eisai seeks to establish a presence in each of the world's top 20 largest pharmaceutical markets, including Canada, by fiscal 2015 in an effort to achieve its objective of making contributions to more than 500 million patients worldwide. By enhancing its sales capabilities with the start of full-scale operations at Eisai Canada, Eisai will further expand its business in Canada, the world's ninth largest pharmaceutical market, and roll out marketing activities tailored to the needs of the local marketplace as its seeks to increase the benefits provided to patients and families throughout the country

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:


Public Relations Department  
Eisai Co. Ltd
T: +81-(0)3-3817-5120

Dec 1, 2011
Source: Eisai
Eisai (TSE: 4523) (U.S: ESALY)
From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary